Scheduled Lectures

April 28
New Perspectives on Timeless Problems: Advanced Reconstructive Solutions Following Urological Cancer Treatment
Boyd Viers, MD
Register now
 Complete evaluation to obtain CME credit
   
May 5
Healthcare Disparities   
Chris Warlick, MD
Register now
Complete evaluation to obtain CME credit
   
May 12 
Management of Hormone Sensitive Metastatic Prostate Cancer: 
Treatment Selection and Therapeutic Intensification    
                   
Ashley Ross, MD
Register now
Complete evaluation to obtain CME credit
   
May 19 
Genomics in Radiation in Postoperative Decision Making              
Daniel Spratt, MD
Register now
Complete evaluation to obtain CME credit
   
May 26 
Kelalis Resident Essay Competition Winners
Presentation of the DC Utz Award for Excellence in Urology
to Dr. Badri Konety
Register now
Complete evaluation to obtain CME credit

  


Thank you to the following companies for their virtual exhibits at our Spring Seminar lecture series.


 

Company website: AbbVie

AbbVie is a global, research-based biopharmaceutical company which combines the focus of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. AbbVie is committed to using unique approaches to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases.

More details: Lupron Depot  

Contact:  Colleen Jensen  |  [email protected]  |  612/398-4991

 


 

Company Website: Ambry Genetics

Why Test

GENETIC TESTING CAN INFORM SCREENING AND MEDICAL MANAGEMENT.  Up to 15% of prostate cancer is hereditary which can also be associated with more aggressive forms of cancer.  Knowing if your patient has hereditary prostate cancer may impact recommendations for treatment and management. For unaffected patients at increased risk, this may mean earlier or more frequent PSA screening.

In one study, over 90% of men with prostate cancer who tested positive had results in a gene that may inform management.  For references see “Germline Testing for Hereditary Prostate Cancer” link below.

Why Ambry

Ambry Genetics, as part of Konica Minolta Precision Medicine, excels at translating scientific research into clinically actionable test results based upon a deep understanding of the human genome and the biology behind genetic disease. Our unparalleled track record of discoveries over 20 years, and growing database that continues to expand in collaboration with academic, corporate and pharmaceutical partners, means we are first to market with innovative products and comprehensive analysis that enable clinicians to confidently inform patient health decisions. We care about what happens to real people, their families, and the people they love, and remain dedicated to providing them and their clinicians with deeper knowledge and fresh insights, so together they can make informed, potentially life-altering healthcare decisions.

Ambry’s High Risk Assessment Platform- CARE

Ambry’s CARE Program was developed to identify patients at increased risk for prostate cancer.  Ambry CARE is a unique end-to-end solution to identify high-risk patients.  CARE provides personalized cancer risk information and facilitates recommendations for increased screening and treatment options.  Additionally, CARE identifies at-risk family members integrating seamlessly into your existing workflow.  Implementing a comprehensive screening and testing program ensures identification of patients at risk for hereditary cancer. 


Handout:
Germline Testing for Hereditary Prostate Cancer 

Handout: ProstateNext Patient Guide 

Handout: Patient Billing Brochure 

Handout: CARE High Risk Identification Video

Handout: CARE Urology One Pager 

Contact: Nicholas Gee | 612-790-8269 | [email protected]

 


  

 

Company website: Coloplast

Coloplast develops products and services that make life easier for people with very personal and private medical conditions. Working closely with the people who use our products, we create solutions that are sensitive to their special needs. Our business includes ostomy care, interventional urology, continence care, wound & skin care.

Video Link: Altis Surgical

Contact: Megan Stadelman  |  612-759-3713  |  [email protected]


 

Company websiteDecipher Urologic Cancers, a part of Veracyte, Inc.

Decipher Urologic Cancers, a part of Veracyte, Inc., is focused on genomic testing to help treatment planning for urologic cancers. 

Decipher's prostate cancer genomic testing provides meaningful and independent data to assess the underlying biology and risk of an individual patient’s disease. The test has been validated in 42 studies of more than 30,000 patients as the most accurate predictor of metastasis, prostate cancer-specific mortality, and overall survival. 

  • Decipher Prostate Biopsy helps determine if patients are suitable for active surveillance, if they need monotherapy, or if they may benefit from multi-modality or intensified therapy. 
  • Decipher Prostate RP helps determine treatment timing following radical prostatectomy and whether patients undergoing salvage radiotherapy may benefit from the addition of ADT.

Developed from a large cohort of post-prostatectomy prostate cancer patients treated at the Mayo Clinic, with long-term follow-up, the whole transcriptome test utilizes 22 coding and non-coding biomarkers that span seven cancer pathways to provide a more accurate, independent prediction of risk.

When used in conjunction with clinical information, Decipher provides clarity and confidence in treatment planning. 

Handouts:  Decipher Prostate Biopsy and Decipher Prostate RP

Product Video: Link

Contact: Andrew Hanson  |  763-245-0620  |  [email protected] 

 


  

Company website: Invitae

Integrating germline genetic testing into your standard of care for patients at risk for or active prostate cancer. Pre-Diagnosis: PSA testing, while useful to screen for prostate cancer, may leave you and your patients with more questions than answers. That’s where genetic testing comes in. Integrating germline genetic testing with PSA testing can help identify patients who may have a genetic predisposition to prostate cancer. Additionally, genetic testing may help you determine whether or not a tumor biopsy is needed. That helps limit invasive interventions and prevent potential complications. Post-diagnosis: Patients under active surveillance may require frequent office visits, screenings, or changes to their treatment regimen. With genetic testing, you can use results to risk stratify those with more aggressive disease progression and: Identify patients in need of more urgent care. Some with particular genetic mutations may benefit from radiation or surgical intervention to reduce the risk of metastasis, improving prognosis and quality of life. Discern patients eligible for new treatments. PARP inhibitors recently received FDA approval for treatment of BRCA- or HRR- mutated mCRPC after previous therapies have failed. Tailor screening measure. Establish how often a patient requires screening, or discover the need for additional cancer screenings, such as pancreatic cancer. Inquire about Detect Prostate: sponsored no-charge testing and counseling for prostate cancer or additional info on insurance billing/coverage/$250 self pay option. 

Handout:  Detect Prostate: Sponsored no-charge testing and counseling

Handout:  Patient guide: Prostate cancer

Handout: Prostate Cancer Case Study: BRCA2

Handout: Prostate Cancer Checklist

Handout: Intercept Study with Mayo & Invitae

Product Video: Link

ContactKyle Veenis  |  651-592-3899  |  [email protected]

 


 

 

 

Company websiteJanssen Biotech, Inc.

At Janssen Biotech, Inc. we have an urgent commitment to make a difference for cancer patients and those living with autoimmune diseases. Comprised of Janssen Oncology and Janssen Immunology, we deliver transformational biologic medicines to market, and have built a rich legacy of innovative firsts. For more information, visit www.janssen.com.

Contact: Tara Molling  |  608-287-6196  |  [email protected]

  


 

 

Company websiteMDxHealth

MDxHealth is a multinational healthcare that provides actionable molecular diagnostic information to personalize the diagnosis of prostate cancer. MDxHealth continues to be at the forefront of improving the diagnostic accuracy of detecting clinically significant prostate cancer. The company utilizes proprietary molecular technologies to advance cancer diagnosis and treatment. MDxHealth's US headquarters and laboratory is located in Irvine, CA.

Product video: Link

Contact: Todd Mercy  |  615-425-6720  |  [email protected]

 


  

Company website: Myovant Sciences

Myovant Sciences. Redefining care for prostate cancer and womens health.

Introducing ORGOVYX- The only FDA approved oral Androgen Deprivation therapy indicated for the treatment of adult patients with advanced prostate cancer.

Handout: Orgovyx Booth Info

Handout: Orgovyx Info for HCPs

Contact: Andrea Barrett  |   [email protected]  |  612/209-6050




Company website: Neotract Teleflex

The UroLift System procedure is a minimally invasive approach to treating BPH that lifts and holds the enlarged prostate tissue out of the way so it no longer blocks the urethra.  There is no cutting, heating or removal of prostate tissue.  It is an early treatment alternative for more BPH patients.

Online resources: Urolift Physicians Page

Contact: Ashley Hunter  |  [email protected]  |  612/300-6692

 


 

Products Represented:  Xtandi (enzalutamide) and Orgovyx (relugolix)

Contact: Colleen Geisler  |  [email protected]  |  651-270-2112

 

 

Interested in a virtual exhibit booth? 
Contact us today for more details!